- Home
- SRPT
as of 11-28-2025 12:39pm EST
$21.00
+$0.05
+0.23%
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
Chart Type:
Time Range:
| Founded: | 1980 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 2.2B | IPO Year: | 1997 |
| Target Price: | $26.00 | AVG Volume (30 days): | 6.1M |
| Analyst Decision: | Hold | Number of Analysts: | 28 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.77 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.41 - $138.81 | Next Earning Date: | 11-03-2025 |
| Revenue: | $2,413,715,000 | Revenue Growth: | 47.15% |
| Revenue Growth (this year): | 10.2% | Revenue Growth (next year): | -22.09% |
AI-Powered SRPT Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 4 days ago
AI Recommendation
hold
Model Accuracy: 73.83%
73.83%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest Sarepta Therapeutics Inc. (DE) News
SRPT Breaking Stock News: Dive into SRPT Ticker-Specific Updates for Smart Investing
MT Newswires
Sarepta Therapeutics Receives FDA Approval for Dosing Levels for Elevidys Study to Treat Duchenne Muscular Dystrophy
📊
AI Sentiment
Positive
7/10
MT Newswires
Arrowhead Pharmaceuticals to Receive $200 Million Payment From Sarepta Therapeutics for Meeting ARO-DM1 Milestone
📊
AI Sentiment
Positive
7/10
Compare SRPT vs Leading Stocks
See how SRPT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "SRPT Sarepta Therapeutics Inc. (DE) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.